Emmessar Biotech & Nutrition Limited (BOM:524768)
India
· Delayed Price · Currency is INR 25.10
+0.54 (2.20%)
At close: Mar 10, 2026
BOM:524768 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 3.74 | 6.11 | 5.55 | 10.19 | 3.65 | 69.91 | Upgrade
|
| Other Revenue | 16.85 | 15.24 | 14.86 | 14.96 | 14.08 | 14.66 | Upgrade
|
| Revenue | 20.59 | 21.35 | 20.42 | 25.15 | 17.73 | 84.56 | Upgrade
|
| Revenue Growth (YoY) | 4.50% | 4.55% | -18.82% | 41.83% | -79.03% | 77.89% | Upgrade
|
| Cost of Revenue | 0.88 | 1.85 | 2 | 4.34 | 1.35 | 35.32 | Upgrade
|
| Gross Profit | 19.7 | 19.49 | 18.42 | 20.81 | 16.38 | 49.24 | Upgrade
|
| Selling, General & Admin | 10.73 | 9.75 | 10.06 | 8.71 | 8.02 | 6.38 | Upgrade
|
| Other Operating Expenses | 5.18 | 4.03 | 4.15 | 3.86 | 2.57 | 19.73 | Upgrade
|
| Operating Expenses | 16.9 | 14.76 | 15.18 | 13.5 | 11.52 | 26.7 | Upgrade
|
| Operating Income | 2.8 | 4.74 | 3.24 | 7.31 | 4.86 | 22.55 | Upgrade
|
| Interest Expense | -0.03 | -0.01 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 4.83 | 4.83 | 4.9 | 2.41 | 2.09 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0.02 | -0.05 | -0.09 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | -0 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 7.62 | 9.58 | 8.12 | 9.67 | 6.87 | 22.55 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.01 | 0.01 | 0.01 | 0 | - | - | Upgrade
|
| Pretax Income | 7.63 | 9.58 | 8.13 | 9.67 | 9.32 | 22.55 | Upgrade
|
| Income Tax Expense | 4.3 | 6.42 | 0.63 | 4.63 | 4.56 | 8.05 | Upgrade
|
| Net Income | 3.33 | 3.16 | 7.5 | 5.04 | 4.75 | 14.5 | Upgrade
|
| Net Income to Common | 3.33 | 3.16 | 7.5 | 5.04 | 4.75 | 14.5 | Upgrade
|
| Net Income Growth | -55.78% | -57.82% | 48.79% | 5.97% | -67.21% | 92.35% | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 0.62% | - | - | - | -0.00% | - | Upgrade
|
| EPS (Basic) | 0.66 | 0.63 | 1.50 | 1.01 | 0.95 | 2.90 | Upgrade
|
| EPS (Diluted) | 0.64 | 0.61 | 1.48 | 1.01 | 0.95 | 2.90 | Upgrade
|
| EPS Growth | -57.56% | -58.78% | 46.77% | 5.97% | -67.21% | 92.35% | Upgrade
|
| Free Cash Flow | - | 2.24 | 6.45 | 3.5 | 19.64 | 4.66 | Upgrade
|
| Free Cash Flow Per Share | - | 0.45 | 1.29 | 0.70 | 3.93 | 0.93 | Upgrade
|
| Gross Margin | 95.71% | 91.32% | 90.21% | 82.75% | 92.38% | 58.23% | Upgrade
|
| Operating Margin | 13.61% | 22.19% | 15.87% | 29.07% | 27.43% | 26.66% | Upgrade
|
| Profit Margin | 16.18% | 14.81% | 36.72% | 20.03% | 26.81% | 17.14% | Upgrade
|
| Free Cash Flow Margin | - | 10.48% | 31.57% | 13.91% | 110.78% | 5.51% | Upgrade
|
| EBITDA | 3.78 | 5.71 | 4.22 | 8.25 | 5.79 | 23.12 | Upgrade
|
| EBITDA Margin | 18.35% | 26.77% | 20.64% | 32.79% | 32.64% | 27.34% | Upgrade
|
| D&A For EBITDA | 0.98 | 0.98 | 0.98 | 0.94 | 0.92 | 0.58 | Upgrade
|
| EBIT | 2.8 | 4.74 | 3.24 | 7.31 | 4.86 | 22.55 | Upgrade
|
| EBIT Margin | 13.61% | 22.19% | 15.87% | 29.07% | 27.43% | 26.66% | Upgrade
|
| Effective Tax Rate | 56.33% | 67.00% | 7.75% | 47.89% | 48.96% | 35.70% | Upgrade
|
| Revenue as Reported | 25.44 | 26.2 | 25.47 | 27.7 | 22.84 | 84.56 | Upgrade
|
| Advertising Expenses | - | 0.23 | 0.22 | 0.17 | 0.17 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.